Therefore, the most promising way might actually be, to use mutant APP impaired in copper and/or zinc binding in different cellular assays, allowing to estimate the pathophysiological impact of copper and zinc on APP function and its role in AD. This evidence concerns the gene APP and Alzheimer disease.